Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Scienture Holdings, Inc. - SIC # 6794 - PATENT OWNERS AND LESSORS
Ticker
Exchange
SIC #
Website
Latest Ticker
SCNX
Nasdaq
6794
scienture.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Scienture Holdings, Inc.
SCIENTURE Reports Q3 2026 Results with Approximately 265% Sequential Revenue Growth Driven by the Commercial Launch of REZENOPY™
- Nov 16th, 2026 6:30 am
SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027
- Oct 22nd, 2026 6:05 am
SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth
- Oct 13th, 2026 6:05 am
EXCLUSIVE: Scienture Revenue Soars 256% As Drugmaker Targets 2027 Profitability
- Oct 13th, 2026 5:45 am
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
- Oct 2nd, 2026 6:05 am
EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions
- Oct 2nd, 2026 5:46 am
Scienture Holdings, Inc. Announces Reverse Stock Split
- Sep 30th, 2026 2:05 pm
SCIENTURE Expands Commercial Reach of REZENOPY™ to Addiction Treatment Centers through an Agreement with a Distribution Partner
- Sep 22nd, 2026 6:15 am
SCIENTURE to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026
- Sep 9th, 2026 6:55 am
SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
- Aug 14th, 2026 6:08 am
SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product
- Aug 12th, 2026 8:13 am
SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
- Aug 12th, 2026 6:05 am
EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US
- Aug 12th, 2026 5:46 am
SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
- Jul 9th, 2026 6:05 am
SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
- Jun 18th, 2026 6:05 am
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
- Jun 9th, 2026 6:05 am
EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch
- Jun 9th, 2026 5:46 am
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
- Jun 2nd, 2026 6:05 am
SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
- May 18th, 2026 6:38 am
Scroll